CRISPR Clinical Trial Update
Apr. 21, 2021
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Anjie Biomedical Technology
Main focus: Next generation CAR-T cells
Company stage: Clinical
Diseases: Solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Guanzhou, China
Anjie Biomedical Technology develops next generation CAR-T cells for solid tumour treatment. The company uses CRISPR to knock out PD-1 from its CAR-T cell products, in order to optimise efficacy and safety.
Tags
Anjie Biomedical Technology Co., Ltd
Clinical Trials
Non-small Cell Lung Cancer, NSCLC, (NCT03525782)
Sponsors:
First Affiliated Hospital of Guangdong Pharmaceutical University
Sponsors:
First Affiliated Hospital of Guangdong Pharmaceutical University
IND Enabling
Phase I
Phase II
Phase III
Prostate Cancer, (NCT03525652)
Sponsors:
The First Affiliated Hospital of Guangdong Pharmaceutical University
Sponsors:
The First Affiliated Hospital of Guangdong Pharmaceutical University
IND Enabling
Phase I
Phase II
Phase III
